Circulating MALAT1 and SCHLAP1 Outperform PSA in Identifying Metastatic Prostate Cancer: A Pilot Biomarker Study

For decades, the standard way to screen for prostate cancer has relied on a blood test that measures a protein called prostate-specific antigen, or PSA. While this test is useful, it is far from perfect. The protein rises not only when cancer is present but also when the prostate is simply inflamed or enlarged, leading to many false alarms and unnecessary biopsies. Even when a biopsy confirms cancer, doctors often struggle to tell the difference between a slow-growing tumor that will never harm a patient and an aggressive one that spreads quickly. This uncertainty leaves many men facing a difficult choice: undergo treatment for a disease that might never progress, or risk waiting too long on a disease that could become deadly. To solve this, scientists have begun looking for new clues hidden in the body's fluids, searching for molecular signals that reveal the true nature of a tumor without needing to cut into the patient.

A promising new avenue involves long non-coding RNAs. These are tiny strands of genetic material that float in the blood and urine, acting as regulators that tell cells how to behave. Unlike the genes that build proteins, these strands do not make proteins themselves; instead, they act like switches and dimmers, turning other genes on or off. In aggressive cancers, these switches often get stuck in the "on" position, driving the tumor to grow and spread. Because these molecules are stable and can be found circulating in the body, they offer a potential way to see the tumor's behavior through a simple blood or urine sample, a method known as a liquid biopsy.

Researchers at several medical institutions in Russia recently set out to test whether specific types of these circulating RNA strands could do a better job than the traditional PSA test at identifying men with metastatic prostate cancer. Metastatic disease is the most dangerous form of the illness, where the cancer has spread from the prostate to other parts of the body. The team focused on seven different RNA strands that had previously shown promise in other studies. They collected blood and urine samples from forty-one men who had already been diagnosed with prostate cancer. The group included men with localized disease that had not spread, as well as twelve men whose cancer had spread to other parts of the body. The researchers measured the levels of each of the seven RNA strands in these samples to see if the amounts differed between the two groups.

The results showed a clear pattern. Every single one of the seven RNA strands was found at higher levels in the men with metastatic disease compared to those with non-metastatic disease. However, when the researchers applied a strict statistical check to ensure the results were not just due to chance, only two of the strands stood out as truly significant. These two were named SCHLAP1 and MALAT1. The levels of these two molecules were much higher in the men with spreading cancer. When the team tested how well these two markers could distinguish between the two groups, they found that both performed better than the Gleason score, a standard method doctors use to grade the severity of cancer based on how the cells look under a microscope. Regarding the PSA test, the study noted that a direct statistical comparison was not possible in this specific context because the PSA levels in the men with metastatic disease were so high that they hit a recording limit, making it impossible to calculate a meaningful accuracy score for PSA against the RNA markers.

The study also looked at whether combining the two best markers would make the test even better. The researchers found that using both SCHLAP1 and MALAT1 together did not improve the ability to tell the groups apart. This suggests that both molecules are providing the same kind of information about the tumor's behavior, rather than offering two different pieces of the puzzle. Furthermore, the levels of these RNA strands did not strongly correlate with the PSA levels or the Gleason score, indicating that they are measuring something distinct about the biology of the cancer. To understand what these molecules might be doing, the team used computer models to map out the biological pathways they are involved in. The analysis revealed that these RNA strands are linked to major cellular processes that drive cancer growth, including pathways that control cell division, how cells use energy, and how they change shape to move through the body.

Despite these encouraging findings, the researchers are careful to note that this is a preliminary study. The group of patients was relatively small, and all the samples came from a single medical center. The study was designed to see if these markers could work, not to prove they are ready for use in every clinic. The authors emphasize that before these RNA tests can replace or supplement current methods, they need to be tested in much larger groups of people across different hospitals. They also note that the study did not include a group of men without cancer to serve as a baseline, which limits how the results can be interpreted for screening the general population. Nevertheless, the work provides strong evidence that these specific RNA strands are biologically linked to the most dangerous forms of prostate cancer and could one day help doctors make more precise decisions about who needs aggressive treatment and who can be monitored more safely.